The most frequent grade 3 and 4 adverse event was lymphopenia, which was reversible

The most frequent grade 3 and 4 adverse event was lymphopenia, which was reversible. [1217]. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib) [2,18], T cell receptor (e.g., CART19) [1922], and NK cells (e.g., AFM13) [2325] are being developed. This review summarized the clinical development in blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3 in patients with relapsed/refractory precursor B cell acute lymphoid leukemia (ALL). == Bispecific antibodies and diabody == Bispecific antibodies (bsAb) was initially developed through hybrid-hybridoma, chemical linkage, or renaturation from purified recombinant Fab or Fv fragment from bacterial inclusion bodies [11,26,27]. One of the major limitations of these technologies is the difficulty in producing sufficient amount of clinical grade bsAbs. This has made the clinical testing of the bsAbs falling behind. Through molecular cloning and/or Amlodipine aspartic acid impurity phage expression library, high affinity recombinant single-chain Fv fragment (scFv) has been produced. This led to the development of bivalent bispecific antibody fragments, diabodies [11,26,27]. A heavy chain scFv (VH) is connected with a light chain scFv (VL) by a short amino acid linker to form a single polypeptide. The short linker is too short to allow self association of the two adjacent VHand VLdomain. Therefore, by linking the VHand VLof two different antibodies A and B to form two different cross-over polypeptide chain VHA-VLB and VHB-VLA, a diabody containing both antigen-binding sites through non-covalent association is formed (Fig.1) [11,26,27]. One such functional small bispecific antibody against EpCAM /CD3 was engineered and purified from Chinese hamster ovary (CHO) cells [27]. This antibody was found to be able to Amlodipine aspartic acid impurity redirect T cells to lyse colon cancer cells expression EpCAM antigen. Using this approach, clinical grade bsAbs were produced from CHO cells in large quantity [23,24,28]. == Fig. 1. == Gene structure and production of bispecific blinatumomab diabody. DNA sequence of the CD19 heavy chain scFv (VHA) is connected with the CD3 light chain scFv (VLB) by a short linker (L) sequence to form a single gene encoding one peptide, VHA-VLB. By the same approach, the DNA sequence of the CD19 light chain scFv (VLA) is connected with the CD3 heavy chain scFv (VHB) by a short linker (L) sequence to form the second gene encoding the other peptide, VHB-VLA. The two polypeptide chains, VHA-VLB and VHB-VLA, can then heterodimerize non-covalently to form a diabody containing bispecific antigen-binding sites to both CD19 and CD3 == Structure and properties of blinatumomab == Combination chemotherapy for relapsed and/or refractory acute lymphoblastic leukemia usually leads to a CR rate in 3045 % of patients and overall survival of 4786 months in first salvage treatment [2933]. CD19 is a common B cell surface marker [3438]. Monoclonal antibodies against CD19 have been in active clinical development [39,40]. In an attempt to develop novel treatment agent for refractory B cell malignancies, a bsAb against CD19/CD3, MT103/MEDI-538 (blinatumomab), was engineered using the diabody approach [41]. One arm of this antibody binds CD19, while the other arm binds CD3 (Fig.2). By redirecting unstimulated primary human T cells against CD19-positive lymphoma cells, the bispecific CD19/CD3 antibody fragment showed significant cytotoxic activity at very low concentrations of 10 to 100 pg/mL and at effector-to-target cell ratios as low as 2:1. This single-chain bispecific antibody construct belongs to a new class of antibody fragments, BiTE [4251]. This bispecific antibody fragment has a molecular weight of 54.1 kDa, approximately one-third of the size of a traditional monoclonal antibody (mAb). As CD19 is an attractive target, CD19 mAb has been widely studied for therapies of lymphoma, leukemia, and autoimmune disorders, such as anti-B4-bR, SAR3419 (huB4-DM4), and Amlodipine aspartic acid impurity BiTE [3840,52]. Blinatumomab can potentiate unstimulated T cells and induce direct cytotoxicity against CD19+ cells [42]. == Fig. 2. == Mechanism of action for blinatumomab as the first-in-class bispecific T cell engager (BiTE). One arm of blinatumomab binds to CD3, the other binds to CD19. This engages the unstimulated T cells Rabbit Polyclonal to Cytochrome P450 19A1 which destroy the CD19+ cells Several properties of blinatumomab promoted its development for immunotherapy of lymphoma and leukemia. Because of its single-chain structure, blinatumomab can be produced with a stable purified monomeric formulation in large quantities for clinical use [23,24,28,41]. Blinatumomab has been shown to increase inflammatory cytokine production, specifically IL-2, IFN-, TNF-, IL-4, IL-6, and IL-10 [53]. Importantly, it can bridge malignant B cells directly to.